Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056]
Titel:
Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056]
Auteur:
Özkan, A. Kapiteijn, E. van den Bos, F. Aarts, M.J.B. van den Berkmortel, F.W.P.J. Blank, C.U. Bloem, M. Blokx, W.A.M. Boers-Sonderen, M.J. Bonenkamp, J.J. van den Eertwegh, A.J.M. de Groot, J.W.B. Haanen, J.B. Holtslag, C.E. Hospers, G.A.P. Piersma, D. van Rijn, R.S. Stevense-den Boer, A.M. Suijkerbuijk, K.P.M. van der Veldt, A.A.M. Vreugdenhil, G. Wouters, M.W.J.M. Portielje, J.E.A. de Glas, N.A.